A Prebiotic Agave Derivated Metlin & Metlos in Infant Formula
NCT ID: NCT01251783
Last Updated: 2010-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
600 participants
INTERVENTIONAL
2010-02-28
2010-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Infant Formula
Infant Formula without lactobaillus or Metlin or Metlos
Infant Formula
Only Infant Formula without Lactobacillus, Metlin OR Metlos
Fully breast milk
Group non randomized with fully breast milk
Exclusively breast milk
Children non randomized which mothers decided to feed them with exclusively breast milk
Metlin+Metlos+Lactobacillus GG
Infant Formula added with Metlin+Metlos (6g/L) and Lactobacillus GG 0.3x107UFC
Metlin+metlos+Lactobacillus GG
A prebiotic Agave Derivated Metlin+Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG
Metlin+Lactobacillus GG
Infant Formula added with Metlin (6g/L) + Lactobacillus GG 0.3x107 UFC
Metlin + Lactobacillus GG
A prebiotic Agave Derivated Metlin (6g/L) + 0.3x107 UFC Lactobacillus GG
Metlos+Lactobacillus GG
Infant Formula added with Metlos (6g/L)+Lactobacillus GG 0.3x107UFC
Metlos + lactobacillus GG
A prebiotic Agave Derivated Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG
Lactobacillus GG
Infant Formula added with Lactobacillus GG 0.3x107UFC without Metlin or Metlos
Lactobacillus GG
An Infant Formula added with 0.3x107 UFC Lactobacillus GG with no Metlin or Metlos
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Infant Formula
Only Infant Formula without Lactobacillus, Metlin OR Metlos
Exclusively breast milk
Children non randomized which mothers decided to feed them with exclusively breast milk
Metlin+metlos+Lactobacillus GG
A prebiotic Agave Derivated Metlin+Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG
Metlin + Lactobacillus GG
A prebiotic Agave Derivated Metlin (6g/L) + 0.3x107 UFC Lactobacillus GG
Metlos + lactobacillus GG
A prebiotic Agave Derivated Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG
Lactobacillus GG
An Infant Formula added with 0.3x107 UFC Lactobacillus GG with no Metlin or Metlos
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 15 ± 7 days at admission
* Birth weight \> 2,490 g.
* Negative history of formula intolerance (only randomized babies)
* Signed Informed Consent
Exclusion Criteria
* Maternal medical history of diabetes (gestational diabetes was acceptable if the infant's birth weight was at or below the percentile 95; or 4153 g or 9 lbs 3 oz for girls or 4340 g or 9 lbs 9 oz for boys
* Tuberculosis, immunologic deficiency, infection disease or perinatal infections known to cause adverse effects in the fetus
* Participation in other study
* Inability of the father/mother or legal tutor to reed or comprehend the informed consent and the symtoms report diary, or
* The infant was part of multiple labor (twins, triplets, etc.)
15 Days
30 Days
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nekutli S.A. de C.V.
UNKNOWN
National Institute of Pediatrics, Mexico
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
National Pediatric of Pediatrics, Mexico
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gabriel Lopez-Vealzquez, PhD
Role: STUDY_DIRECTOR
National Insitute of Pediatrics, Mexico
Pedro Gutierrez-Castrellon, MD, MSc, DSc
Role: PRINCIPAL_INVESTIGATOR
National Institute of Pediatrics, Mexico
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Pediatric Institute
Mexico City, Mexico City, Mexico
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Leach JD, Sobolik KD. High dietary intake of prebiotic inulin-type fructans in the prehistoric Chihuahuan Desert. Br J Nutr. 2010 Jun;103(11):1558-61. doi: 10.1017/S0007114510000966. Epub 2010 Apr 26.
Gomez E, Tuohy KM, Gibson GR, Klinder A, Costabile A. In vitro evaluation of the fermentation properties and potential prebiotic activity of Agave fructans. J Appl Microbiol. 2010 Jun;108(6):2114-21. doi: 10.1111/j.1365-2672.2009.04617.x. Epub 2009 Nov 4.
Lopez MG, Mancilla-Margalli NA, Mendoza-Diaz G. Molecular structures of fructans from Agave tequilana Weber var. azul. J Agric Food Chem. 2003 Dec 31;51(27):7835-40. doi: 10.1021/jf030383v.
Gruber C, van Stuijvenberg M, Mosca F, Moro G, Chirico G, Braegger CP, Riedler J, Boehm G, Wahn U; MIPS 1 Working Group. Reduced occurrence of early atopic dermatitis because of immunoactive prebiotics among low-atopy-risk infants. J Allergy Clin Immunol. 2010 Oct;126(4):791-7. doi: 10.1016/j.jaci.2010.07.022. Epub 2010 Sep 15.
Sazawal S, Dhingra U, Hiremath G, Sarkar A, Dhingra P, Dutta A, Verma P, Menon VP, Black RE. Prebiotic and probiotic fortified milk in prevention of morbidities among children: community-based, randomized, double-blind, controlled trial. PLoS One. 2010 Aug 13;5(8):e12164. doi: 10.1371/journal.pone.0012164.
Sabater-Molina M, Larque E, Torrella F, Zamora S. Dietary fructooligosaccharides and potential benefits on health. J Physiol Biochem. 2009 Sep;65(3):315-28. doi: 10.1007/BF03180584.
Lopez-Velazquez G, Parra-Ortiz M, Mora Ide L, Garcia-Torres I, Enriquez-Flores S, Alcantara-Ortigoza MA, Angel AG, Velazquez-Aragon J, Ortiz-Hernandez R, Cruz-Rubio JM, Villa-Barragan P, Jimenez-Gutierrez C, Gutierrez-Castrellon P. Effects of Fructans from Mexican Agave in Newborns Fed with Infant Formula: A Randomized Controlled Trial. Nutrients. 2015 Oct 29;7(11):8939-51. doi: 10.3390/nu7115442.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Metlin&MetlosChildren
Identifier Type: -
Identifier Source: org_study_id